TITLE

Thiazolidinediones and Risk of Heart Failure

PUB. DATE
April 2010
SOURCE
Travel Medicine Advisor;Apr2010 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates on the safety use of drugs in the U.S. A report revealed that the use of Thiazolidinediones (TZDs) is associated on the increased risk for cardiovascular diseases. The use of selective-serotonin reuptake inhibitor (SSRI) with tamoxifen reduces the risks of women with breast cancer to higher breast cancer mortality. The Food and Drug Administration (FDA) has warned the use of long-acting beta agonists (LABAs) drugs for it adds to the worsening of symptoms in asthma.
ACCESSION #
49039650

 

Related Articles

  • Drug to prevent breast cancer near approval. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);09/12/98, Vol. 317 Issue 7160, p697 

    Reports that a scientific advisory panel of the United States Food and Drug Administration voted to approve the drug, tamoxifen, as a preventative measure in reducing the incidence of breast cancer in healthy women who are at high risk for developing breast cancer. In-depth look at the concerns...

  • Tamoxifen Prevention of Breast Cancer: an Instance of the fingerpost. Lippman, Scott M.; Brown, Powel H. // JNCI: Journal of the National Cancer Institute;11/03/99, Vol. 91 Issue 21, p1809 

    Examines studies regarding tamoxifen's role in breast cancer prevention. Role of the Breast Cancer Prevention Trial's findings in the United States Food and Drug Administration's approval of tamoxifen as chemopreventive agent for breast cancer; Breast cancer prevention studies in Europe; Trials...

  • Breast cancer prevention trials `can re-start'. Gavaghan, Helen // Nature;6/16/1994, Vol. 369 Issue 6481, p515 

    Reports on the recommendation by the Food and Drug Administration oncology advisory committee that the clinical trial of the breast cancer drug tamoxifen should be allowed to continue despite claims that it increases women's chances of developing endometrial cancer. National Cancer Institute's...

  • Raloxifene examined for breast cancer prevention. Young, Donna // American Journal of Health-System Pharmacy;9/1/2007, Vol. 64 Issue 17, p1774 

    The article reports that raloxifene examined for breast cancer prevention in the U.S. The Food and Drug Administration (FDA) advisory panel gave its approval for the osteoporosis drug raloxifene to be used as an oral chemopreventive agent for invasive breast cancer. The panelists said that the...

  • Avandia Adcom Looks Down Track Toward Other Drugs. Serebrov, Mari // BioWorld Today;6/11/2013, Vol. 24 Issue 111, p1 

    The article reports that members of the Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management Advisory Committees of the U.S. Food and Drug Administration (FDA) voted to loosen the restrictions on prescribing Glaxosmithline plc's (GSK) diabetes drug, Avandia. They told FDA...

  • FDA panel recommends expanded diabetes drug testing. Haigh, Christen // Endocrine Today;7/25/2008, Vol. 6 Issue 13, p1 

    The article reports on the recommendation of a U.S. Food & Drug Administration (FDA) advisory committee to drug companies to expand their tests on anti-diabetic drugs. These tests should be done in order to ensure that there is no increased cardiovascular disease risk in patients taking these drugs.

  • Diabetes, Glycemia and Cardiovascular Disease: Is it Time to Rethink the Regulatory Approach.  // MD Conference Express;Aug2010, p35 

    The article reports on the approval of the new regulations on handling new diabetes drugs by the U.S. Food and Drug Administration (FDA). It discusses the arguments pertaining the approval of the drugs for the treatment of diabetes as well as the arguments on holding the regulatory status quo....

  • FDA Offers Path for Contrave Approval; Orexigen Soars.  // Bioworld Week;9/26/2011, Vol. 19 Issue 38, p1 

    The article reports on the possible approval of the diet pill Contrave from Orexigen Therapeutics Inc. by the U.S. Food And Drug Administration (FDA), after the company's meeting with the agency's Office of New Drugs. The FDA gave the company a chance to resolve its complete response letter...

  • FDA Actions.  // Infectious Disease Alert;Nov2010 Clinical Bri, p2 

    The article reports on the drugs that were approved or restricted by the U.S. Food and Drug Administration (USFDA). Rosiglitazone, a drug for type 2 diabetes, was restricted due to its association with the increased risk of cardiovascular disease. The FDA has approved fingolimod an oral drug for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics